MedMira, a developer and manufacturer of diagnostics and technologies, has received the US Army Medical Research Acquisition Activity (USAMRAA) contract valued at $2,278,192 to develop a multi-marker test for the detection of the Hepatitis B Core IgG and IgM antibodies.
US Army will fund development costs and associated fees to obtain the US Food and Drug Administration (FDA) premarket approval (PMA) for the new test, as per the contract number W81XWH-11-C-0090.
The Hepatitis B test will be deployed in medical operations to screen blood supplies for transfusion transmitted diseases in critical care situations.
The test is also used in occupational exposure, medical surveillance programs, and routine pre and post deployment medical checks.
MedMira CEO Hermes Chan said the work undertaken within this project is aligned with its competencies in developing multi-marker infectious disease diagnostics on their technology platform.
"This contract is a foundation upon which to build an ongoing partnership with the US Army that enabled MedMira to provide tools with frontline implications in military medical care," Chan said.